Development of chronic kidney disease (CKD) is a common consequence of many medical conditions, and its prevalence is rising. Predominant causes of CKD are hypertension and diabetes mellitus. Determination of Glomerular Filtration Rate (GFR) is one of the most common tests employed and a part of all standard blood panels. GFR is used to assess kidney functioning. GFR is consequently the most important marker for impaired renal function.
Currently, GFR determination is based on an estimation using clinical data and blood based biomarkers such as creatinine. GFR can either be measured (mGFR) by tracer based methods or estimated (eGFR) using clinical data and blood based biomarkers such as creatinine or cystatin C. However, mGFR methods are highly elaborate and time-consuming and eGFR lacks accuracy in a variety of common clinical situations. As a consequence clinical decision making is difficult especially early when intervention may retard progression to end-stage renal disease.
Numares developed a novel multi-parametric serum test to significantly improve serum creatinine-based glomerular filtration rate estimation to allow for a more accurate and easy assessment of renal (kidney) function.
This would improve the treatment of patients with (chronic) renal diseases and monitoring of therapies with nephrotoxic drugs.
More information on the AXINON® System:
Go to FAQs
The test will be available for the AXINON® System, which produces high-quality, standardized NMR spectra based on Numares’ Magnetic Group Signaling (MGS®) technology, which enables a throughput of more than 200 samples per day.
The combination of MGS® with the AXINON® System allows for spectral analysis with highly-reproducible results. The system is easy to use requiring minimal operator interaction. It is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
To date, more than 2 million tests have been performed worldwide using Numares’ technology.
